ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ATNX Athenex Inc

0.2031
0.00 (0.00%)
Pre Market
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.2032
Ask Price 0.2033
News -
Day High

Low
0.2016

52 Week Range

High
1.66

Day Low
Company Name Stock Ticker Symbol Market Type
Athenex Inc ATNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.2031 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.2031
Trades Volume Avg Volume 52 Week Range
0 0 - 0.2016 - 1.66
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.2031 USD

Athenex Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.76M - - - -15.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Athenex News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ATNX Message Board. Create One! See More Posts on ATNX Message Board See More Message Board Posts

Historical ATNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year1.661.660.20160.6060652294,535-1.46-87.77%
3 Years97.40115.000.201643.511,974,481-97.20-99.79%
5 Years249.40440.000.201698.781,480,174-249.20-99.92%

Athenex Description

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Your Recent History

Delayed Upgrade Clock